Application of diosmin at intrahepatic portal hypertension
Abstract
Aim of investigation. To study efficacy of phlebodia-600 (diosmin) in treatment of portal hypertension at patients with liver cirrhosis (LC).
Methods. Comparative investigation of efficacy of monotherapy by enalapril (10 mg/day) and phlebodia600 (1200 mg/day), and their combination at portal hypertension has been carried out at 35 patients with LC of Child-Pugh classes A and B.
Results. Phlebodia-600 more significantly, than enalapril, decreased diameter of portal and splenic veins, but had no essential effect on peripheral blood flow velocity. Combined treatment by these agents along with decrease of diameter of veins significantly increased average rate of blood flow in portal vein and decreased splenic venous blood flow. The average value of congestive index in portal vein at monotherapy by enalapril decreased by 30,5%, at application of phlebodia-600 – by 26,0%, at their combined application – by 51,4%. The combined treatment significantly decreased hepatic artery resistance index (by 25%) as well.
Conclusion. Combined application of enalapril and phlebodia-600 in the treatment of portal hypertension is more effective, than monotherapy.
About the Authors
G. K. Mirodzhov
Институт гастроэнтерологии АМН МЗ Республики Таджикистан
Tajikistan
Tajikistan
S. A. Avezov
Институт гастроэнтерологии АМН МЗ Республики Таджикистан
Tajikistan
Tajikistan
M. M. Giyasov
Институт гастроэнтерологии АМН МЗ Республики Таджикистан
Tajikistan
Tajikistan
S. G. Mirodzhova
Институт гастроэнтерологии АМН МЗ Республики Таджикистан
Tajikistan
Tajikistan
References
1. Кириенко А.И., Богачев В.Ю., Золотухин И.А., Голованова О.В. Полусинтетический диосмин (Флебодиа 600) в лечении хронической венозной недостаточности нижних конечностей // Ангиология и сосудистая хирургия. – 2006. – Т. 12, № 2. – С. 73–75.
2. Мансуров Х.Х. Портальная гипертензия и заболевания сосудов печени. – Душанбе, 2005. – 135 с.
3. Мироджов Г.К., Авезов С.А., Тухтаева Н.С. и др. Продолжительность жизни больных и прогностическое значение проявлений и осложнений цирроза печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – Т. 20, № 5. – С. 27–32.
4. Покровский А.В., Сапелкин С.В. Производные полусинтетического диосмина в лечении больных с ХВН – результаты проспективного исследования с применением препарата флебодиа 600 // Ангиология и сосудистая хирургия. – 2005. – Т. 11, № 4. – С. 73–79.
5. Bataller R., Schwabe R.F., Choi Y.H. et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis // J. Clin. Invest. – 2003. – Vol. 112. – P. 1383–1394.
6. Bosch J., Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension // J. Hepatol. – 2000. – Vol. 32 (suppl. 1). – P. 141–156. // Semin. Liver Dis. – 1999. – Vol. 19. – P. 475–505.
7. D’Amico G., Pagliaro L., Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach // Semin. Liver Dis. – 1999. – Vol. 19. – P. 475–505
8. Debernardi-Venon W., Barletti C., Alessandria C. et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension // Dig. Dis. Sci. – 2002. – Vol. 47. – P. 401–404.
9. Friedman S.L. The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common // J. Hepatol. – 2004. – Vol. 40. – P. 1050–1052.
10. Laleman W., van Landeghem L., Wilmer A. et al. Portal hypertension: from pathophysiology to clinical practice // Liver Int. – 2005. – Vol. 25, N 6. – P. 1079–1090.
11. Rathbun S.W., Kirkpatrick A.C. Treatment of chronic venous insufficiency // Curr. Treat. Options Cardiovasc. Med. – 2007. – Vol. 9, N 2. – P. 115–126.
12. Villeneuve J.P., Pomier-Layrargues G., InfanteRivard C. et al. Propanolol for the prevention of recurrent variceal rebleeding in cirrhosis: a controlled trial // Hepatology. – 1986. – Vol. 6. – P. 1239–1243.
Review
For citations:
Mirodzhov G.K., Avezov S.A., Giyasov M.M., Mirodzhova S.G. Application of diosmin at intrahepatic portal hypertension. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(1):40-43. (In Russ.)
Views:
147
Email this article 
